EcoDrugPlus

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSATEG00000017119
Gene Symbol: LOC113163206
2 Cross references
270 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSATEG00000025533
Gene Symbol: LOC113164875
2 Cross references
292 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSATEG00000025740
Gene Symbol: SLC10A2
3 Cross references
211 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSATEG00000005173
Gene Symbol: SLC18A2
3 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6, Like

Ensembl ID : ENSATEG00000019840
Gene Symbol: SLC22A6L
3 Cross references
360 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSATEG00000017774
Gene Symbol: SLC5A1
3 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSATEG00000021955
Gene Symbol: SLC5A2
3 Cross references
199 Possible Orthologues:

Solute Carrier Family 6 Member 1a

Ensembl ID : ENSATEG00000015611
Gene Symbol: SLC6A1A
3 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 1b

Ensembl ID : ENSATEG00000024986
Gene Symbol: SLC6A1B
3 Cross references
208 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSATEG00000002473
Gene Symbol: SLC6A2
3 Cross references
204 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSATEG00000024157
Gene Symbol: SLC6A3
1 Cross references
167 Possible Orthologues:

Solute Carrier Family 6 Member 4a

Ensembl ID : ENSATEG00000022940
Gene Symbol: SLC6A4A
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).